Zhuhai Rundu Pharmaceutical Co., Ltd.
SZSE:002923.SZ
12.55 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,291.887 | 1,372.234 | 1,189.927 | 1,252.631 | 1,359.908 | 1,043.86 | 779.421 | 651.862 | 577.943 | 523.598 | 434.131 | 361.934 | 311.18 |
| Cost of Revenue
| 638.762 | 600.79 | 458.836 | 460.885 | 379.964 | 260.263 | 275.659 | 235.111 | 194.668 | 174.071 | 145.712 | 130.999 | 102.314 |
| Gross Profit
| 653.125 | 771.444 | 731.091 | 791.746 | 979.944 | 783.597 | 503.762 | 416.751 | 383.274 | 349.527 | 288.419 | 230.935 | 208.865 |
| Gross Profit Ratio
| 0.506 | 0.562 | 0.614 | 0.632 | 0.721 | 0.751 | 0.646 | 0.639 | 0.663 | 0.668 | 0.664 | 0.638 | 0.671 |
| Reseach & Development Expenses
| 129.443 | 95.591 | 92.14 | 102.466 | 114.541 | 66.023 | 44.693 | 30.05 | 18.635 | 16.123 | 12.94 | 11.517 | 0 |
| General & Administrative Expenses
| 30.375 | 23.599 | 15.24 | 52.297 | 50.995 | 25.293 | 17.802 | 12.536 | 15.707 | 12.571 | 32.79 | 30.462 | 57.639 |
| Selling & Marketing Expenses
| 314.629 | 389.552 | 416.654 | 440.989 | 661.568 | 563.767 | 311.943 | 261.628 | 248.26 | 233.678 | 183.764 | 133.566 | 106.165 |
| SG&A
| 345.004 | 413.151 | 431.894 | 493.287 | 712.563 | 589.06 | 329.745 | 274.164 | 263.967 | 246.25 | 216.554 | 164.027 | 163.805 |
| Other Expenses
| -0.227 | 44.295 | 47.275 | 36.508 | 23.286 | -0.126 | -2.152 | 15.648 | 4.562 | 5.618 | 8.981 | 7.353 | 3.209 |
| Operating Expenses
| 511.281 | 553.037 | 571.309 | 632.261 | 850.39 | 674.313 | 390.599 | 326.904 | 301.75 | 279.823 | 222.61 | 169.019 | 168.086 |
| Operating Income
| 86.267 | 181.354 | 153.784 | 153.581 | 133.553 | 119.841 | 103.964 | 85.714 | 78.372 | 64.171 | 60.92 | 59.765 | 39.59 |
| Operating Income Ratio
| 0.067 | 0.132 | 0.129 | 0.123 | 0.098 | 0.115 | 0.133 | 0.131 | 0.136 | 0.123 | 0.14 | 0.165 | 0.127 |
| Total Other Income Expenses Net
| -56.532 | -0.414 | -2.047 | -4.75 | -1.111 | 10.431 | -11.351 | 11.081 | 1.305 | -0.227 | 4.025 | 4.77 | 1.867 |
| Income Before Tax
| 86.04 | 180.939 | 151.737 | 148.831 | 132.442 | 119.715 | 101.812 | 100.928 | 82.829 | 69.477 | 69.833 | 66.686 | 42.646 |
| Income Before Tax Ratio
| 0.067 | 0.132 | 0.128 | 0.119 | 0.097 | 0.115 | 0.131 | 0.155 | 0.143 | 0.133 | 0.161 | 0.184 | 0.137 |
| Income Tax Expense
| 19.141 | 25.462 | 11.971 | 12.969 | 13.545 | 12.871 | 11.159 | 13.462 | 11.664 | 9.957 | 10.474 | 10.09 | 10.435 |
| Net Income
| 66.899 | 155.477 | 139.766 | 135.862 | 118.897 | 106.844 | 90.653 | 87.466 | 71.165 | 59.52 | 59.359 | 56.596 | 32.212 |
| Net Income Ratio
| 0.052 | 0.113 | 0.117 | 0.108 | 0.087 | 0.102 | 0.116 | 0.134 | 0.123 | 0.114 | 0.137 | 0.156 | 0.104 |
| EPS
| 0.2 | 0.46 | 0.42 | 0.41 | 0.36 | 0.33 | 0.37 | 0.36 | 0.29 | 0.24 | 0.24 | 0.23 | 0.13 |
| EPS Diluted
| 0.2 | 0.46 | 0.42 | 0.41 | 0.36 | 0.32 | 0.37 | 0.36 | 0.29 | 0.24 | 0.24 | 0.23 | 0.13 |
| EBITDA
| 257.02 | 292.546 | 221.562 | 206.499 | 175.613 | 151.819 | 139.385 | 126.601 | 102.307 | 89.308 | 68.866 | 63.552 | 41.235 |
| EBITDA Ratio
| 0.199 | 0.213 | 0.186 | 0.165 | 0.129 | 0.145 | 0.179 | 0.194 | 0.177 | 0.171 | 0.159 | 0.176 | 0.133 |